Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice

T. Maruyama, K. Watanabe, I. Takei, A. Kasuga, A. Shimada, T. Yanagawa, T. Kasatani, Y. Suzuki, K. Kataoka, T. Saruta, S. Habu

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


To elucidate the role of natural killer (NK) cells in the pathogenesis of diabetes in the non-obese diabetic (NOD) mouse, we examined whether or not cyclophosphamide-induced diabetes occurs in NOD mice intraperitoneally (i.p.) injected with anti-asialo GM1 antibody. Two weeks after a single intraperitoneal injection of cyclophosphamide, none of the 24 NOD mice which had previously been treated with anti-asialo GM1 antibody, 2-3 times per week for either 2 or 3 weeks, had developed indications of diabetes such as glycosuria or a high plasma glucose level. On the other hand, signs of diabetes were found in 10 of 24 control NOD mice injected with normal rabbit Ig instead of anti-asialo GM1 antibody (p<0.01). The NK cell activities of spleen cells from anti-asialo GM1 antibody-treated mice were significantly lower than those of control mice (p<0.01). Flowcytometry analysis demonstrated that anti-asialo GM1 antibody-positive cells had disappeared from the spleens of anti-asialo GM1 antibody-injected mice but no suppression of CD8+ and CD4+ cells could be demonstrated. These observations suggest that NK cells are involved in the development of diabetes in NOD mice.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalDiabetes Research
Issue number1
Publication statusPublished - 1991
Externally publishedYes


  • Anti-asialo GM1 antibody
  • Cyclophosphamide
  • NK-cell
  • NOD mouse
  • Prevention

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'Anti-asialo GM1 antibody suppression of cyclophosphamide-induced diabetes in NOD mice'. Together they form a unique fingerprint.

Cite this